PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Sacubitril/valsartan - Heart failure
PAD Profile : Sacubitril/valsartan - Heart failure Important
Keywords :
Sacubitril, CHF, valsartan, neprilysin inhibitor, angiotensin receptor antagonist
Brand Names Include :
Entresto
Important Information :
Do not co-administer with an ACEi or ARB due to risk of angioedema.
Traffic Light Status
Status 1 of 2.
Status :
Amber
Formulations :
- Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Status 2 of 2.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Eplerenone
- Ivabradine
- Digoxin
- Spironolactone
- Dapagliflozin
- Empagliflozin
- Metolazone
- Ramipril
- Captopril
- Enalapril maleate
- Lisinopril
- Perindopril erbumine
- Bisoprolol fumarate
- Carvedilol
- Nebivolol
- Candesartan cilexetil
- Losartan potassium
- Valsartan
- Prazosin hydrochloride
- Hydralazine hydrochloride
- Acetazolamide
- Enoximone
- Milrinone lactate
Other Indications
Additional Documents
Type
Document
Review Date
Shared Care
31 March 2020
Shared Care
31 March 2020
Committee Recommendations
Date
Committee Name
Narrative
01 June 2016
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN recommends Sacubitril/Valsartan (Entresto®) for treating symptomatic chronic heart failure with reduced ejection fraction in line with NICE guidance (TA388 – April 2016) and will be considered as AMBER on the traffic light system. CCGs in conjunction with local Acute Trusts will make local implementation plans as required
Associated BNF Codes
02. Cardiovascular System
02.05.05. Renin-angiotensin system drugs